Beyond Genomics Forges First Corporate Deal | GenomeWeb

NEW YORK, May 15 – Beyond Genomics said Tuesday it has entered its first corporate partnership, penning a deal with Elan Pharmaceuticalsto apply its systems biology techniques for Alzheimer's research.

In exchange for Beyond Genomics’ two-year commitment to the program, during which the companies will seek to find biomarkers and drug targets for Alzheimer's disease, Elan made a $5 million equity investment in the company.

Beyond Genomics did not disclose any more financial details.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.